https://www.linkedin.com/in/albert-bourla
About
I became Chief Executive Officer at Pfizer, one of the world's premier innovative biopharmaceutical companies, on January 1, 2019.
In my previous role as Chief Operating Officer (COO), I oversaw the company's commercial, strategy, manufacturing and global product development functions.
Prior to being named COO, I was the Group President of Pfizer Innovative Health, responsible for the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. I also created the Patient and Health Impact group, which is dedicated to developing solutions for increasing patient access, demonstrating the value of our innovations, and ensuring broader business model innovation.
I have 25 years of experience with Pfizer and have held a number of senior global positions across a range of markets and disciplines. Previously, I was the Group President of Pfizer's Global Vaccines, Oncology and Consumer Healthcare business. Before that, I was President and General Manager of Pfizer's Established Products business, leading the development and implementation of strategies and tactics related to Pfizer's off-patent portfolio (including legacy brands and generics).
I've also held a number of positions of increasing responsibility in Animal Health and Marketing. Prior to joining Pfizer, I was a practicing Veterinarian in Greece.
I am a board member for the Pfizer Foundation, which promotes access to quality health care and the Biotechnology Innovation Organization (Bio), the world's largest biotechnology trade association, where I serve on the Executive Committee.